Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Global Pharmaceutical Sales Expected To Reach $880 Billion In 2011 With China Fueling Growth

This article was originally published in PharmAsia News

Executive Summary

The pharmaceutical market will grow faster in 2011 than it is expected to grow in 2010, but the industry faces tough times ahead, IMS Health, the market research and consulting firm, said on Oct. 7

You may also be interested in...

China's Largest Private Drug Distributor, Jointown, Seeks Initial Public Offering In Shanghai

SHANGHAI - To compete with the country's largest drug distributor SinoPharm, China's third-ranked Jointown recently filed for an initial public offering in Shanghai to raise roughly RMB 899.8 million ($135.4 million) to expand a distribution network in seven key regions across China

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts